The global demand for EGFR-TKI for Advanced NSCLC Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% during the period of 2022-2028.
EGFR-TKI for Advanced NSCLC refers to as epidermal growth factor receptor- tyrosine kinase inhibitors for advance non-small-cell lung cancer. EGFR-TKI is a substance that blocks or resists the action of enzymes called tyrosine kinases. These enzymes are too active or found at high levels in -small-cell lung cancer, and preventing them help keep cancer cells from growing. It is superior to chemotherapy in terms of progression-free survival (PFS) and objective response rate. Gefitinib, Erlotinib, Afatinib, and Osimertinib are TKIs approved for the treatment of EGFR NSCLC.
Market Dynamics
Lung cancer is a leading cause of death worldwide, accounting for an estimated 2.09 million cases in 2018. NSCLC is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. The rising burden of non-small-cell lung cancer is driving the growth of the market. Continuing advances in research and treatment provide opportunities for the market. Companies are are continually looking for new molecules with the enhanced potential to cure NSCLC. The rising R& D activities and growing approval for the TKIs will further amplify market growth. However, researchers are facing many challenges in terms of its effectiveness, which is obstructing new inventions, and hence market growth.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of EGFR-TKI for Advanced NSCLC.
Market Segmentation
The entire EGFR-TKI for Advanced NSCLC market has been sub-categorized into type and application. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Type
- Gefitinib
- Erlotinib
- Afatinib
- Osimertinib
By Application
- Combination Therapy
- Mono Therapy
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for EGFR-TKI for Advanced NSCLC market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global EGFR-TKI for Advanced NSCLC Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the EGFR-TKI for Advanced NSCLC market include Henan DaKen Chemical, Capot Chemical Co.,Ltd., Chemwill Asia Co.,Ltd., MSN Labs, Sun Pharma, Amadis Chemical, Chongqing Chemdad Co., Ltd., Mylan, Alchem Pharmtech,Inc. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.